- Home
- IMCR vs DMLP Comparison
IMCR vs DMLP Comparison
Compare IMCR & DMLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- DMLP
- Stock Information
- Founded
- IMCR 2008
- DMLP 2003
- Country
- IMCR United Kingdom
- DMLP United States
- Employees
- IMCR N/A
- DMLP N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- DMLP Oil & Gas Production
- Sector
- IMCR Health Care
- DMLP Energy
- Exchange
- IMCR Nasdaq
- DMLP Nasdaq
- Market Cap
- IMCR 1.5B
- DMLP 1.4B
- IPO Year
- IMCR 2021
- DMLP N/A
- Fundamental
- Price
- IMCR $28.40
- DMLP $27.90
- Analyst Decision
- IMCR Buy
- DMLP
- Analyst Count
- IMCR 11
- DMLP 0
- Target Price
- IMCR $59.11
- DMLP N/A
- AVG Volume (30 Days)
- IMCR 265.8K
- DMLP 82.7K
- Earning Date
- IMCR 05-07-2025
- DMLP 05-08-2025
- Dividend Yield
- IMCR N/A
- DMLP 11.43%
- EPS Growth
- IMCR N/A
- DMLP N/A
- EPS
- IMCR N/A
- DMLP 2.03
- Revenue
- IMCR $333,581,000.00
- DMLP $166,824,000.00
- Revenue This Year
- IMCR $20.26
- DMLP N/A
- Revenue Next Year
- IMCR $8.49
- DMLP N/A
- P/E Ratio
- IMCR N/A
- DMLP $13.77
- Revenue Growth
- IMCR 25.75
- DMLP 12.09
- 52 Week Low
- IMCR $23.15
- DMLP $25.84
- 52 Week High
- IMCR $62.22
- DMLP $34.88
- Technical
- Relative Strength Index (RSI)
- IMCR 45.68
- DMLP 43.43
- Support Level
- IMCR $27.88
- DMLP $26.97
- Resistance Level
- IMCR $31.38
- DMLP $28.30
- Average True Range (ATR)
- IMCR 1.60
- DMLP 0.71
- MACD
- IMCR -0.08
- DMLP -0.10
- Stochastic Oscillator
- IMCR 22.19
- DMLP 31.21
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.